Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases.
[Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases]. Orv Hetil. 2017 Dec;158(52):2051-2061 Authors: Halmos T, Suba I Abstract Non-alcoholic fatty liver disease is the most common non-infectious chronic liver-disease in our age, and is a spectrum of all the diseases associated with increased fat accumulation in the hepatocytes. Its development is promoted by sedentary life-style, over-feeding, and certain genetic predisposition. Prevalence in the adult population, even in Hungary is ~30%. In a part of cases, this disease may pass into non-alcoholic steatohepatitis, later into fibrosis, rarely into primary hepatocellular cancer. Fatty liver is closely and bidirectionally related to the metabolic syndrome and type 2 diabetes, and nowadays there is a general consensus that fatty liver is the hepatic manifestation of the metabolic sycndrome. The importance of the fatty liver has been highly emphasized recently. In addition to the progression into steatohepatitis, its causal relationship with numerous extrahepatic disorders has been discovered. In our overview, we deal with the epidemiology, pathomechanism of the disease, discuss the possibilities of diagnosis, its relationship with the intestinal microbiota, its recently recognized correlations with bile acids and their receptors, and its supposed correlations with the circadian CLOCK system. Hereinafter, we overview those...
Publication date: Available online 1 April 2020Source: Journal of Molecular LiquidsAuthor(s): Xianting Xie, Lu Zhang, Wenjuan Zhang, Reza Tayebee, Atefe Hoseininasr, Hamid H. Vatanpour, Zeinab Behjati, Suying Li, Marjan Nasrabadi, Liuyi Liu
Publication date: Available online 1 April 2020Source: Carbohydrate PolymersAuthor(s): Chia-Hsiang Yen, Sheng-Tien Li, Nai-Chen Cheng, You-Ren Ji, Jyh-Horng Wang, Tai-Horng Young
CONCLUSIONS: Our study results corroborate earlier findings that the CSF tool is of added value to the diagnostic workup in daily clinical practice outside tertiary referral centers. CSF levels can best be used in patients under 66 years of age. Given the limited use of this tool in settings outside research facilities, we recommend that the usefulness of CSF biomarkers is studied in a multicenter study. When in the future CSF levels can be reliably measured in plasma, this may become even more relevant. PMID: 32224618 [PubMed - as supplied by publisher]
Publication date: Available online 1 April 2020Source: The Journal of Chemical ThermodynamicsAuthor(s): Shihua Dong, Weizhen Sun, Yueyang Jiang, Bing Jia
Publication date: Available online 1 April 2020Source: Inorganica Chimica ActaAuthor(s): Sourav De, S.K. Ashok Kumar
Publication date: Available online 1 April 2020Source: European Polymer JournalAuthor(s): Himani Kalita, Manoj Patowary
Chem. Commun., 2020, Advance Article DOI: 10.1039/D0CC00513D, CommunicationZhongyan Wang, Chuanrui Ma, Yuna Shang, Lijun Yang, Jing Zhang, Cuihong Yang, Chunhua Ren, Jinjian Liu, Guanwei Fan, Jianfeng Liu An ingenious co-assembled nanosystem based on fenofibrate and ketoprofen peptide for the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Conclusions: The mapping algorithms reported in this paper can be used to predict the EQ-5D-5L utilities from the PDI; however, similar to other mapping studies in the literature it can only serve as the second-best approach to elicit utilities from disease-specific instruments. PMID: 32223358 [PubMed - as supplied by publisher]
The coronavirus has been a far deadlier threat in New Orleans than the rest of the United States, with a per-capita death rate much higher than in New York City.Reuters Health Information
Conclusion: CD26 is involved in the pathogenesis of colorectal diseases; sCD26 is diminished in CRC patients suggesting the potential utility of a sCD26 for diagnosis. PMID: 32223519 [PubMed - as supplied by publisher]
More News: Alcoholism | Alzheimer's | Bariatric Surgery | Bile | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Epidemiology | Fatty Liver Disease (FLD) | General Medicine | Genetics | Heart | Hungary Health | Inflammatory Bowel Disease | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Orthopaedics | Osteoporosis | Psoriasis | Sleep Apnea | Sleep Disorders | Sleep Medicine | Urology & Nephrology